Classic familial adenomatous polyposis
Rare disease
Yes
- Definition
- Familial adenomatous polyposis (FAP) is characterized by the development of hundreds to thousands of adenomas in the rectum and colon during the second decade of life.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Classic familial adenomatous polyposis
- classic familial adenomatous polyposis
- FAP
- Familial Adenomatous Polyposis
- adenomatous polyposis coli
- classic FAP
- classic familial adenomatous polyposis
- colorectal adenomatous polyposis
- familial adenomatous polyposis
- familial adenomatous polyposis coli
- familial adenomatous polyposis syndrome
- familial polyposis
- familial polyposis coli
- hereditary adenomatous polyposis coli
- polyposis coli
- FPC
- familial adenomatous polyposis of the colon
- familial multiple polyposis
- hereditary polyposis coli
- Severity
- Severe
- Genetic
- Hereditary
- Syndromic
- MONDO ID
- MONDO:0021055
- Parent condition
- MONDO:0021057
Related records
Broader conditions (15)
- Cancer or benign tumor
- Classic or attenuated familial adenomatous polyposis
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Disease susceptibility
- Hereditary disease
- Hereditary neoplastic syndrome
- Human disease
- Inherited disease susceptibility
- Intestinal polyposis syndrome
- Neoplastic disease or syndrome
- Neoplastic syndrome
- Syndromic disease
Narrower conditions (3)
- Familial adenomatous polyposis due to 5q22.2 microdeletion
- Gardner syndrome
- Turcot syndrome with polyposis
Trials (109)
- 18F-FAPI PET in the Diagnosis of Liver Fibrosis
- 18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
- 18F-FES PET/CT in Imaging Patients With Desmoid Tumors
- 68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG
- 68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
- A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
- A Clinical Trial of the Effectiveness and Safety of Software Assisting Diagnose the Intestinal Polyp Digestive Endoscopy by Analysis of Colonoscopy Medical Images From Electronic Digestive Endoscopy Equipment
- A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
- A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
- A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).
- A Study of Guselkumab in Participants With Familial Adenomatous Polyposis
- A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
- A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
- A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
- A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
- Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy
- An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery
- An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
- Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions
- Azithromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
Approved drugs (1)
Drugs in development (22)
- Aspirin Phase 3
- Bevacizumab Phase 1
- Calcitriol Phase 3
- Calcium carbonate Phase 3
- Curcumin Phase 2
- Eflornithine Phase 3
- Eflornithine hydrochloride Phase 3
- Eflornithine, (S)- Phase 3
- Erlotinib Phase 2
- Erlotinib hydrochloride Phase 2
- Guselkumab Phase 1
- Icosapent Phase 3
- Inulin Phase 2
- Lactobacillus acidophilus Phase 2
- Lithium carbonate Phase 2
- Metformin Phase 2
- Niclosamide Phase 2
- Obeticholic acid Phase 1
- Sirolimus Phase 2
- Sulindac Phase 3